Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BACR & ECMC: Therapeutic interventions for cancer prevention /
Chemoprevention of breast cancer recurrence

18th - 19th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.08.16
Views: 1717

Prof Rob Coleman – The University of Sheffield, Sheffield, UK

Prof Coleman speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about bone-targeted agents that have links to reducing breast cancer incidence.

He describes results from trials of bisphosphonate and denosumab, a well tolerated antibody which inhibits RANK ligand pathways.

Prof Coleman also relates the ongoing IBIS III study of bisphosphonates to reduce recurrence and relapse of breast cancer, and considers the future of chemoprevention in health care.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation